Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 23

Sort by

Sort Order Select

Journal Articles

Defibrotide Interaction With Newer Oral Anticoagulant and Antiplatelet Drugs

Jawed Fareed, Ph.D., Michael J Moorman, III, Walter Jeske, Ph.D., Debra Hoppensteadt, Ph.D.

Blood (2013) 122 (21): 4804.

https://doi.org/10.1182/blood.V122.21.4804.4804

Published: 2013

Journal Articles

Generic Low Molecular Weight Heparins May Not Have the Same Safety –Efficacy Profile As the Branded Low Molecular Weight Heparins in Acute Coronary Syndrome

Debra Hoppensteadt, Ph.D., Walter Jeske, Ph.D., Jeanine M. Walenga, PhD, Bruce E Lewis, MD, Jawed Fareed, PhD

Blood (2011) 118 (21): 2308.

https://doi.org/10.1182/blood.V118.21.2308.2308

Published: 2011

Journal Articles

Product Associated Variation in Generic Enoxaparin. Potential Clinical Implications

Jawed Fareed, PhD, Debra Hoppensteadt, Ph.D., Albara Ottman, Omer Iqbal, MD, Walter Jeske, Ph.D., Angel Gray, Jeanine M. Walenga, PhD, Evi Kalodiki, PhD, Indermohan Thethi, MD, Rakesh Wahi, MD

Blood (2011) 118 (21): 1249.

https://doi.org/10.1182/blood.V118.21.1249.1249

Published: 2011

Journal Articles

Pharmacodynamic Differences in the Two Generic Brands of Enoxaparin

Debra Hoppensteadt, Ph.D., Walter Jeske, Ph.D., Angel Gray, Jeanine M. Walenga, PhD, Rakesh Wahi, MD, Indermohan Thethi, MD, Jawed Fareed, PhD

Blood (2011) 118 (21): 1251.

https://doi.org/10.1182/blood.V118.21.1251.1251

Published: 2011

Journal Articles

Prevalence of Heparin Induced Thrombocytopenia Antibodies During the Period 2004–2011. Relevance to Heparin Contaminants

Jawed Fareed, PhD, Cafer Adiguzel, MD, Debra Hoppensteadt, Ph.D., Walter Jeske, Ph.D., Jeanine M. Walenga, PhD, Bruce E Lewis, MD, Harry L. Messmore, Jr., MD, Vinod Bansal, MD

Blood (2011) 118 (21): 4326.

https://doi.org/10.1182/blood.V118.21.4326.4326

Published: 2011

Journal Articles

Should Generic Versions of Low Molecular Weight Heparins Be Considered As Generic or Biosimilar Drugs. A Regulatory Dilemma

Jawed Fareed, PhD, Walter Jeske, Ph.D., Debra Hoppensteadt, Ph.D., Rakesh Wahi, MD, Russell D Hull

Blood (2011) 118 (21): 4328.

https://doi.org/10.1182/blood.V118.21.4328.4328

Published: 2011

Journal Articles

Comparison of Branded Enoxaparin (Lovenox) and a Biosimilar Version of Enoxaparin (Fibrinox)

Walter Jeske, Ph.D., Elizabeth McGeehan, MA, CVT, Omer Iqbal, MD, Debra Hoppensteadt, Ph.D., Jeanine M. Walenga, PhD, Jawed Fareed, PhD

Blood (2010) 116 (21): 4385.

https://doi.org/10.1182/blood.V116.21.4385.4385

Published: 2010

Journal Articles

Effect of Heparin:PMX60056 Complexes on Platelet Aggregation Induced by ADP or HIT Antibody

Walter Jeske, Ph.D., R. Eric McAllister, MD, DPhil, Jeanine M. Walenga, PhD, Michelle Paulus, Jawed Fareed, PhD

Blood (2010) 116 (21): 4386.

https://doi.org/10.1182/blood.V116.21.4386.4386

Published: 2010

Journal Articles

Comparative Studies on An Anti-Xa Enriched Ultra Low Molecular Weight Heparin with Bemiparin

Debra Hoppensteadt, Ph.D., Angel Gray, Josephine Cunanan, MD, Walter Jeske, Ph.D., Jeanine M. Walenga, PhD, Jawed Fareed, PhD

Blood (2010) 116 (21): 4394.

https://doi.org/10.1182/blood.V116.21.4394.4394

Published: 2010

Journal Articles

An Open Label, Non Randomized, Propspective Phase IV Clinical Trial Evaluating the Immunogenicity of Branded Enoxaparin Versus Biosimilars In Healthy Volunteers.

Marise Gomes, Ph.D., Eduardo Ramacciotti, M.D., Ph.D., Debra Hoppensteadt, Ph.D., Jeanine M. Walenga, PhD, Bruce E Lewis, MD, Walter Jeske, Ph.D., Jawed Fareed, PhD

Blood (2010) 116 (21): 1086.

https://doi.org/10.1182/blood.V116.21.1086.1086

Published: 2010

Journal Articles

Arylamides: Discovery of a Novel Class of Fully-Synthetic Small Molecule Heparin and LMWH Antagonists.

Richard W. Scott, Ph.D., Michael J. Costanzo, Ph.D., Katie B. Freeman, Ph.D., Robert W. Kavash, Ph.D., Trevor M. Young, William F. DeGrado, Ph.D., Walter Jeske, Ph.D.

Blood (2010) 116 (21): 1096.

https://doi.org/10.1182/blood.V116.21.1096.1096

Published: 2010

Journal Articles

Generic Versions of Low Molecular Weight Heparin May Not Have the Same Safety-Efficacy Profile as the Branded Low Molecular Weight Heparins In Acute Coronary Syndrome.

Debra Hoppensteadt, Ph.D., Walter Jeske, Ph.D., Evangelos Litinas, MD, Omer Iqbal, MD, Jeanine M. Walenga, PhD, Bruce E Lewis, MD, Hussein Kahn, M.D., Jawed Fareed, PhD

Blood (2010) 116 (21): 1098.

https://doi.org/10.1182/blood.V116.21.1098.1098

Published: 2010

Journal Articles

Optimized Fully-Synthetic Salicylamide Heparin Antagonists Have Greater Efficacy Versus LMWHs and Display Improved Hemodynamic Responses as Compared to Protamine

Richard W. Scott, Ph.D., Michael J. Costanzo, Ph.D., Katie B. Freeman, Ph.D., Robert W. Kavash, Ph.D., Trevor M. Young, William F. DeGrado, Ph.D., Walter Jeske, Ph.D.

Blood (2010) 116 (21): 191.

https://doi.org/10.1182/blood.V116.21.191.191

Published: 2010

Journal Articles

Novel Antagonists for Low Molecular Weight Heparin and Heparin-Like Drugs.

Walter Jeske, Ph.D., Christine Schroeder, Margaret Prechel, Ph.D., Jeanine M. Walenga, PhD, Mamdouh Bakhos, M.D.

Blood (2009) 114 (22): 2092.

https://doi.org/10.1182/blood.V114.22.2092.2092

Published: 2009

Journal Articles

Prevalence of Anti-Heparin Platelet Factor 4 Antibodies in Patients with Disseminated Intravascular Coagulation.

Jawed Fareed, He Zhu, MD, Josephine Cunanan, Walter Jeske, Ph.D., Debra Hoppensteadt, Hussain Arif, Messmore Harry, Jeanine M. Walenga, PhD

Blood (2009) 114 (22): 2094.

https://doi.org/10.1182/blood.V114.22.2094.2094

Published: 2009

Journal Articles

Enoxaparin Produces Sustained Antithrombotic Effects in Comparison to Fondaparinux and Rivaroxaban: Clinical Implications.

Walter Jeske, Ph.D., Nicholas Masse, Joseph Emanuele, He Zhu, MD, Elizabeth McGeehan, Jawed Fareed, Mamdouh Bakhos, M.D., Jeanine M. Walenga, PhD

Blood (2009) 114 (22): 3128.

https://doi.org/10.1182/blood.V114.22.3128.3128

Published: 2009

Journal Articles

Prolonged Administration of Defibrotide Is Non-Immunogenic in Rats and Dogs.

Jawed Fareed, Debra Hoppensteadt, Josephine Cunanan, Walter Jeske, Ph.D., Cafer Adiguzal, He Zhu, MD, Cinara Echart, Massimo Iacobelli

Blood (2009) 114 (22): 4180.

https://doi.org/10.1182/blood.V114.22.4180.4180

Published: 2009

Journal Articles

Increased Antithrombotic and Bleeding Effects of Contaminated Heparins; Hematological Implications

Evangelos Litinas, MD, Walter Jeske, Ph.D., Debra Hoppensteadt, Ph.D., Harry Messmore, MD, Jeanine M. Walenga, PhD, Jawed Fareed, Ph.D.

Blood (2008) 112 (11): 3021.

https://doi.org/10.1182/blood.V112.11.3021.3021

Published: 2008

Journal Articles

AVE5026: A New Hemisynthetic Ultra Low Molecular Weight Heparin with Enriched Anti-Xa Activity and Enhanced Antithrombotic Activity for Management of Cancer Associated Thrombosis

Debra Hoppensteadt, Ph.D., Walter Jeske, Ph.D., Jeanine M. Walenga, PhD, Jawed Fareed, Ph.D.

Blood (2008) 112 (11): 4046.

https://doi.org/10.1182/blood.V112.11.4046.4046

Published: 2008

Journal Articles

Molecular and Functional Heterogeneity in Contaminants Isolated from Recalled Heparin. Impact on Anticoagulation and Potential Adverse Reactions

Jawed Fareed, Ph.D., Debra Hoppensteadt, Ph.D., Walter Jeske, Ph.D., Cafer Adiguzel, MD, Omer Iqbal, MD, Jeanine M. Walenga, PhD

Blood (2008) 112 (11): 4048.

https://doi.org/10.1182/blood.V112.11.4048.4048

Published: 2008

NARROW

Defibrotide Interaction With Newer Oral Anticoagulant and Antiplatelet Drugs

Generic Low Molecular Weight Heparins May Not Have the Same Safety –Efficacy Profile As the Branded Low Molecular Weight Heparins in Acute Coronary Syndrome

Product Associated Variation in Generic Enoxaparin. Potential Clinical Implications

Pharmacodynamic Differences in the Two Generic Brands of Enoxaparin

Prevalence of Heparin Induced Thrombocytopenia Antibodies During the Period 2004–2011. Relevance to Heparin Contaminants

Should Generic Versions of Low Molecular Weight Heparins Be Considered As Generic or Biosimilar Drugs. A Regulatory Dilemma

Comparison of Branded Enoxaparin (Lovenox) and a Biosimilar Version of Enoxaparin (Fibrinox)

Effect of Heparin:PMX60056 Complexes on Platelet Aggregation Induced by ADP or HIT Antibody

Comparative Studies on An Anti-Xa Enriched Ultra Low Molecular Weight Heparin with Bemiparin

An Open Label, Non Randomized, Propspective Phase IV Clinical Trial Evaluating the Immunogenicity of Branded Enoxaparin Versus Biosimilars In Healthy Volunteers.

Arylamides: Discovery of a Novel Class of Fully-Synthetic Small Molecule Heparin and LMWH Antagonists.

Generic Versions of Low Molecular Weight Heparin May Not Have the Same Safety-Efficacy Profile as the Branded Low Molecular Weight Heparins In Acute Coronary Syndrome.

Optimized Fully-Synthetic Salicylamide Heparin Antagonists Have Greater Efficacy Versus LMWHs and Display Improved Hemodynamic Responses as Compared to Protamine

Novel Antagonists for Low Molecular Weight Heparin and Heparin-Like Drugs.

Prevalence of Anti-Heparin Platelet Factor 4 Antibodies in Patients with Disseminated Intravascular Coagulation.

Enoxaparin Produces Sustained Antithrombotic Effects in Comparison to Fondaparinux and Rivaroxaban: Clinical Implications.

Prolonged Administration of Defibrotide Is Non-Immunogenic in Rats and Dogs.

Increased Antithrombotic and Bleeding Effects of Contaminated Heparins; Hematological Implications

AVE5026: A New Hemisynthetic Ultra Low Molecular Weight Heparin with Enriched Anti-Xa Activity and Enhanced Antithrombotic Activity for Management of Cancer Associated Thrombosis

Molecular and Functional Heterogeneity in Contaminants Isolated from Recalled Heparin. Impact on Anticoagulation and Potential Adverse Reactions

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only